Literature DB >> 12428729

Acute mitochondrial and chronic toxicological effects of 1-methyl-4-phenylpyridinium in human neuroblastoma cells.

Stacy E Stephans1, Gary W Miller, Allan I Levey, J Timothy Greenamyre.   

Abstract

At low micromolar concentrations, 1-methyl-4-phenylpyridinium (MPP+), the toxic metabolite of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) selectively kills nigrostriatal dopaminergic neurons by mechanisms believed to involve impairment of mitochondrial complex I. A human neuroblastoma cell line expressing the dopamine transporter (DAT) was utilized to examine the effects of MPP+ on acute physiologic responses and subsequent cell death. Acute responses were measured by microphysiometry and by monitoring mitochondrial membrane potential with [3H]tetraphenylphosphonium (TPP+) uptake. MPP+ (10 microM) increased extracellular proton excretion in DAT-expressing cells within 2-3 min, but had no effect in untransfected cells. The lipophilic complex I inhibitor, rotenone, increased proton excretion in both cell lines. In DAT-expressing cells, mitochondrial membrane potential was reduced within I h of 10 microM MPP+ exposure. Rotenone reduced mitochondrial membrane potential in both cell lines. MPP+ caused apoptotic death of DAT-transfected cells 2-3 days after drug application, but did not kill untransfected cells. Thus, MPP+ produces immediate mitochondrial impairment only in cells that express DAT, and these changes occur days before overt cellular toxicity. The magnitude, time course and nature of these changes were similar to those produced by rotenone, confirming the site of action of MPP+ as mitochondrial complex I. These immediate mitochondrial effects appear to be an accurate predictor of subsequent cell death.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12428729     DOI: 10.1016/s0161-813x(02)00060-8

Source DB:  PubMed          Journal:  Neurotoxicology        ISSN: 0161-813X            Impact factor:   4.294


  9 in total

1.  Disruption of dopamine transport by DDT and its metabolites.

Authors:  Jaime M Hatcher; Kristin C Delea; Jason R Richardson; Kurt D Pennell; Gary W Miller
Journal:  Neurotoxicology       Date:  2008-04-29       Impact factor: 4.294

2.  DLP1-dependent mitochondrial fragmentation mediates 1-methyl-4-phenylpyridinium toxicity in neurons: implications for Parkinson's disease.

Authors:  Xinglong Wang; Bo Su; Wanhong Liu; Xiaohua He; Yuan Gao; Rudy J Castellani; George Perry; Mark A Smith; Xiongwei Zhu
Journal:  Aging Cell       Date:  2011-06-14       Impact factor: 9.304

3.  Pyrethroid pesticide-induced alterations in dopamine transporter function.

Authors:  Mohamed A Elwan; Jason R Richardson; Thomas S Guillot; W Michael Caudle; Gary W Miller
Journal:  Toxicol Appl Pharmacol       Date:  2005-07-11       Impact factor: 4.219

4.  Coenzyme Q10, hyperhomocysteinemia and MTHFR C677T polymorphism in levodopa-treated Parkinson's disease patients.

Authors:  Gaetano Gorgone; Monica Currò; Nadia Ferlazzo; Giulia Parisi; Lucilla Parnetti; Vincenzo Belcastro; Nicola Tambasco; Aroldo Rossi; Francesco Pisani; Paolo Calabresi; Riccardo Ientile; Daniela Caccamo
Journal:  Neuromolecular Med       Date:  2012-02-22       Impact factor: 3.843

5.  An in vitro model of Parkinson's disease: linking mitochondrial impairment to altered alpha-synuclein metabolism and oxidative damage.

Authors:  Todd B Sherer; Ranjita Betarbet; Amy K Stout; Serena Lund; Melisa Baptista; Alexander V Panov; Mark R Cookson; J Timothy Greenamyre
Journal:  J Neurosci       Date:  2002-08-15       Impact factor: 6.167

6.  Disruption of lateral olivocochlear neurons with a dopaminergic neurotoxin depresses spontaneous auditory nerve activity.

Authors:  Colleen G Le Prell; David F Dolan; Larry F Hughes; Richard A Altschuler; Susan E Shore; Sanford C Bledsoe
Journal:  Neurosci Lett       Date:  2014-08-29       Impact factor: 3.046

7.  Characterization of membrane potential-dependent uptake of the novel PET tracer 18F-fluorobenzyl triphenylphosphonium cation.

Authors:  Igal Madar; Hayden Ravert; Barry Nelkin; Masroor Abro; Martin Pomper; Robert Dannals; James J Frost
Journal:  Eur J Nucl Med Mol Imaging       Date:  2007-09-05       Impact factor: 9.236

8.  Chronic treatment with the complex I inhibitor MPP+ depletes endogenous PTEN-induced kinase 1 (PINK1) via up-regulation of Bcl-2-associated athanogene 6 (BAG6).

Authors:  Manish Verma; Jianhui Zhu; Kent Z Q Wang; Charleen T Chu
Journal:  J Biol Chem       Date:  2020-04-24       Impact factor: 5.157

Review 9.  PPAR agonists as therapeutics for CNS trauma and neurological diseases.

Authors:  Shweta Mandrekar-Colucci; Andrew Sauerbeck; Phillip G Popovich; Dana M McTigue
Journal:  ASN Neuro       Date:  2013-12-18       Impact factor: 4.146

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.